Does Henry H. Du have family or related-party ties at Emmaus Life Sciences (EMMA)?

The company reports there are no family relationships between Henry H. Du and any current directors, executive officers, or nominees. It also notes he is not party to any current or proposed transaction that would require disclosure under Item 404(a) of Regulation S-K.

Emmaus Life Sciences adds Henry Du to board

Emmaus Life Sciences, Inc. appointed Henry H. Du to its Board of Directors by written consent on April 16, 2026, filling the vacancy created by the recent resignation of Jon Kuwahara.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Emmaus Life Sciences, Inc. appointed Henry H. Du to its Board of Directors by written consent on April 16, 2026, filling the vacancy created by the recent resignation of Jon Kuwahara. He is also expected to replace Mr. Kuwahara as the sole member of the Board’s Audit Committee.

Mr. Du, age 48, is Vice President – Finance Accounting and interim Chief Financial Officer of Alpha Cognition, Inc., a biopharmaceutical company, and is a Certified Public Accountant with a Bachelor of Arts degree from Claremont McKenna College. Emmaus states there are no family relationships or related-party transactions requiring disclosure, and that he will be compensated like its other directors.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Appointment date: April 16, 2026 Director age: 48 years Alpha Cognition role start: October 2024

3 metrics

Appointment date April 16, 2026 Date directors appointed Henry H. Du to the Board

Director age 48 years Age of Henry H. Du as disclosed

Alpha Cognition role start October 2024 Start date of Du’s role at Alpha Cognition, Inc.

Key Terms

Audit Committee, emerging growth company, Regulation S-K

3 terms

Audit Committee financial

"expected to also be appointed to replace Mr. Kuwahara as the sole member of the Audit Committee of the Board"

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

emerging growth company regulatory

"Securities registered pursuant to Section 12(b of the Act ... Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Regulation S-K regulatory

"not party to any current or proposed transaction for which disclosure is required under Item 404(a) of Regulation S-K"

A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did Emmaus Life Sciences (EMMA) disclose?

Emmaus Life Sciences disclosed that its directors appointed Henry H. Du to the Board to fill a vacancy created by the recent resignation of Jon Kuwahara. Du is also expected to serve as the sole member of the company’s Audit Committee, replacing Kuwahara in that role.

What is Henry H. Du’s current role outside Emmaus Life Sciences (EMMA)?

Henry H. Du currently serves as Vice President – Finance Accounting and interim Chief Financial Officer of Alpha Cognition, Inc., a biopharmaceutical company in Grapevine, Texas. Alpha Cognition focuses on developing novel therapeutics for debilitating neurodegenerative disorders, a background relevant to Emmaus’s life sciences focus.

Will Henry H. Du’s compensation at Emmaus Life Sciences (EMMA) differ from other directors?

Emmaus Life Sciences states that Henry H. Du is expected to be compensated for his services in the same manner as its other directors. The company does not describe any special compensation arrangements or unique benefits, indicating he will participate under the standard director compensation framework.

What are Henry H. Du’s professional qualifications for the Emmaus Life Sciences (EMMA) board?

Henry H. Du is a Certified Public Accountant and has held senior finance and accounting roles at various life sciences and other companies. He holds a Bachelor of Arts degree from Claremont McKenna College, providing both technical accounting expertise and industry experience to Emmaus’s Board of Directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/17/2026 - 05:16 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 16, 2026

Emmaus Life Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-35527		87-0419387
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

21250 Hawthorne Boulevard, Suite 800, Torrance, CA		90503
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (310) 214-0065

(Former name or former address, if changed, since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

Securities registered pursuant to Section 12(b of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers

Appointment of Director

By written consent on April 16, 2026, the directors of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) appointed Henry H. Du to fill the vacancy on the Board of Directors created by the recent resignation of Jon Kuwahara. Mr. Du is expected to also be appointed to replace Mr. Kuwahara as the sole member of the Audit Committee of the Board.

Mr. Du, age 48, has served as the Vice President – Finance Accounting and interim Chief Financial Officer of Alpha Cognition, Inc. (NASDAQ: ACOG), Grapevine, Texas, a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, since October 2024. Prior to joining Alpha Cognition, Inc., Mr. Du served in senior finance and accounting positions with a number of life sciences and other companies. Mr. Du is a Certified Public Accountant and holds a Bachelor of Arts degree from Claremont McKenna College, Claremont, California.

There are no family relationships between Mr. Du and any of our other directors, executive officers, or persons nominated or chosen to become a director or executive officer. Mr. Du is expected to be compensated for his services in the same manner as our other directors, and is not party to any current or proposed transaction for which disclosure is required under Item 404(a) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 17, 2026	EMMAUS LIFE SCIENCES, INC.

	By:	/s/ WILLIS LEE
	Name:	Willis Lee
	Title:	Chairman and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents